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ABSTRACT
Tregs can contribute to tumor progression by suppressing antitumor immunity. Exceptionally, in human
colorectal cancer (CRC), Tregs are thought to exert beneficial roles in controlling pro-tumor chronic
inflammation. The goal of our study was to characterize CRC-infiltrating Tregs at multiple levels, by
phenotypical, molecular and functional evaluation of Tregs from the tumor site, compared to non-tumoral
mucosa and peripheral blood of CRC patients. The frequency of Tregs was higher in mucosa than in blood,
and further significantly increased in tumor. Ex vivo, those Tregs suppressed the proliferation of tumor-
infiltrating CD8C and CD4C T cells. A differential compartmentalization was detected between Helioshigh
and Helioslow Treg subsets (thymus-derived versus peripherally induced): while Helioslow Tregs were
enriched in both sites, only Helioshigh Tregs accumulated significantly and specifically in tumors, displayed
a highly demethylated TSDR region and contained high proportions of cells expressing CD39 and OX40,
markers of activation and suppression. Besides the suppression of T cells, Tregs may contribute to CRC
progression also through releasing IL-17, or differentiating into Tfr cells that potentially antagonize a
protective Tfh response, events that were both detected in tumor-associated Tregs. Overall, our data
indicate that Treg accumulation may contribute through multiple mechanisms to CRC establishment and
progression.
Abbreviations: CRC, colorectal cancer; CT, center of the tumor; HCC, hepatocellular carcinoma; IM, invasive margin;
NT, non-tumor; PB, peripheral blood; PBMC, peripheral blood mononuclear cells; SNP, single nucleotide polymor-
phism; T, tumor; Tconv, conventional T cell; Tfh, T follicular helper; Tfr, T follicular regulatory; Th17, T helper 17;
Treg, regulatory T cell; TSDR, Treg-specific demethylated region
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Introduction
An appropriate balance between effector and regulatory activities
ensures mounting of protective immune responses while limiting
tissue damage. Regulatory T cells (Tregs), a CD4C T cell subset
specialized in immune suppression, crucially maintain immune
system homeostasis in physiological conditions. However, in
chronic inflammatory diseases and cancer, the effector/regulatory
equilibrium may be persistently perturbed, finally leading to a
failed eradication of the primary injury. Indeed, in a variety of
experimental tumor models and human cancers, the relative pro-
portion of Tregs, with respect to effector T cells, is significantly
increased at the tumor site and correlate with an adverse progno-
sis. We have recently shown that, in human liver carcinogenesis,
Treg expansion is an early event, occurring already in a prema-
lignant condition, i.e. cirrhosis. Such expanded Tregs display a
phenotype (Helioshigh, OX40C, CD39C) that is suggestive of a
strong immune suppressive activity in vivo.1
Contrary to the majority of cancer types, in colorectal cancer
(CRC), a high Treg density at the tumor site (evaluated by
immunohistochemistry) has been associated to a better out-
come.2-4 This finding led to hypothesize that, in CRC,
Treg-mediated suppression of chronic inflammation may pre-
vail over the control of antitumor immunity.3,5 However, other
data strongly suggest that Tregs do not inhibit but rather pro-
mote pro-tumor Th17 responses,6 and actively suppress
tumor-specific CD8C T cell activation in CRC patients.7-9
Besides CD8C T cell infiltration,10 the occurrence of ectopic
lymphoid tissue, often localized at the invasive cancer front,
has a favorable prognostic impact for early stage CRC.11 Spe-
cialized Treg subsets, such as T follicular regulatory cells (Tfr),
are devoted to antagonize follicular responses.12 The goal of
our study was to characterize at several levels (phenotypical,
functional and epigenetic) the Tregs infiltrating human CRC
specimens, in order to assess whether they exerted suppressive
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function ex vivo, presented a Helioshigh, OX40C, CD39C pheno-
type and displayed Th17-like or Tfr properties.
Results
Suppressive Tregs accumulate at tumor site in CRC
patients
First, we estimated the frequency of Tregs, identified as
CD127lowFOXP3C/CD4C T cells, in peripheral blood (PB),
tumor fragments (T) and specimens of normal colonic mucosa
(NT) of CRC samples, through flow cytometry. Confirming
previous results (mostly obtained through the analysis of
CD25C and/or FOXP3C cells),7,9,3 we observed that Treg
proportion slightly increased in NT, compared to PB, but was
massively expanded in T, compared to both PB and NT
(Fig. 1A–B). Ex vivo Treg depletion resulted in an enhanced
proliferation, following polyclonal stimulation, of both conven-
tional T cells (CD4CFOXP3¡, Tconvs) and CD8C T cells from
PB, NT and T (Fig. 1C–D); notably, the extent of the rescue in
CD8C and Tconv proliferation, following Treg depletion, was
significantly enhanced in T samples (Fig. 1E), suggesting that
the relative impact of Treg suppression was more relevant in
the tumor microenvironment, likely due to the higher Treg
proportions at that site.
However, we did not detect in our cohort any significant dif-
ference in T-derived (T-)Treg frequency in CRC patients with
different stage (Fig. S1A) or grade (Fig. S1B). As a surrogate
indicator for tumor outcome, we evaluated the CD3C cell den-
sity in the center of the tumor (CT) and at the invasive margin
(IM), previously recognized as a strong predictor of favorable
prognosis in CRC.10 In line with published data,10 CD3C cell
densities in IM and CT, as evaluated by immunohistochemis-
try, showed positive correlation (Fig. S2A), and both tended to
decrease with stage (Fig. S2B). When patients were stratified
according to high/low CD3C cell density at IM or CT, we could
observe that Treg frequency paralleled, despite not significantly,
the CD3C scoring in NT or T sites (Fig. S1C–D).
T-Tregs are mostly Helioshigh and carry demethylated TSDR
The human Treg pool contains several subsets with distinct
proliferative and suppressive potentialities,14 and Treg hetero-
geneity has been found also in pre-malignant and malignant
Figure 1. Suppressive Tregs accumulate at T site in CRC patients. (A–B) Representative CD127/FOXP3 staining (A) and percentages of Tregs (B) in gated CD4C T cells in PB,
NT and T samples of CRC patients (n D 31). p < 0 .05, p < 0 .001, by Wilcoxon matched-pairs test, two-tailed. In all figures, Tregs and Tconvs have been identified as
FOXP3C CD127low or FOXP3¡, respectively, within the CD14¡ CD16¡ CD56¡ CD19¡ viability dye¡ CD4C gate. (C–E) CFSE profile overlay (C), mean fluorescence intensity
(MFI) of CFSE (D), and percentage of inhibition of CFSE dilution (E) in gated Tconvs (CD4CFOXP3¡) or CD8C T cells from Treg-depleted or total (Ctrl) mononuclear cells,
obtained from a representative CRC patient. The experiment was repeated thrice with cells of individual patients giving similar results. p < 0 .05, p < 0 .01,
p < 0 .005, by Student t test, unpaired.
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liver tissue microenvironment.1 Therefore, we performed mul-
tiparameter flow cytometry to better characterize Treg diversity
in NT and T specimens from CRC patients. First, we focused
on the transcription factor Helios, which has been associated to
the thymic origin, to a stronger suppressive function 15 and to a
more stable regulatory program 16 maintained by epigenetic
events, i.e., demethylation in the Treg-specific demethylated
region (TSDR) of the FOXP3 locus.1 The frequency of
Helioshigh Tregs significantly increased only in T (Fig. 2A–B),
in line with data in hepatocellular carcinoma (HCC).1 Con-
versely, the proportion of Helioslow Tregs accumulated in both
NT and T, compared to PB, possibly as a physiological conse-
quence of colonic Treg induction in response to food and
microbial antigens.17 To support the relationship between
Helios expression and regulatory stability, we analyzed the level
of TSDR methylation in highly purified Helioshigh or Helioslow
Tregs or Tconvs isolated from the PB or NT specimen (but not
from T specimen, because of the paucity of lymphocytes
extracted from the T district that did not allow these assays
requiring very high number of cells). Notably, Helioshigh, but
not Helioslow, Tregs from different sites displayed a highly
demethylated TSDR (Fig. 2C), a strong indicator of a commit-
ted regulatory program also in tumors.18
OX40 expression supports Treg survival and proliferation
in CRC
Our previous data revealed that HCC-infiltrating Tregs expressed
high level of OX40, an event that was related to a superior immune
suppressive function.1 Based on the observation of a pivotal role of
OX40 in supporting Treg fitness in experimental models of gut
inflammation,19,20 we investigated whether Treg expansion in CRC
was related to higher levels of OX40 expression. Indeed, we found
that the frequency of both OX40C Tconvs and Tregs significantly
increased in NT andmuchmore in T samples (Fig. 3A–B); in addi-
tion, OX40 was always more represented in Tregs than in Tconvs
(Fig. 3A–B), even though the extent of OX40 expression in the two
subsets showed a positive correlation in all districts (Fig. 3D). Look-
ing within the Treg gate, OX40 was upregulated in NT and T sam-
ples in both Helioslow and Helioshigh Tregs and the two events were
positively associated, despite it was always higher on the Helioshigh
counterpart (Fig. 3C and E).
To better evaluate the net impact of OX40 stimulation
on the whole CRC-infiltrating T cells, we stimulated in vitro
mononuclear cells extracted from T specimens of CRC
patients in the presence of crosslinked rOX40L: our results
indicated that OX40 engagement promoted the proliferation
Figure 2. Helioshigh, epigenetically stable, Tregs specifically increase in tumor. (A–B) Representative Helios/FOXP3 staining in overlaid Helioshigh Tregs (red), Helioslow
Tregs (blue) and Tconvs (gray) (A) and percentages of Helioslow and Helioshigh Tregs in gated CD4C T cells (B) in PB, NT and T of CRC patients (n D 21). p < 0 .01,
p < 0 .005, p < 0 .001, by Wilcoxon matched-pairs test, two-tailed. ns, not significant. (C) The indicated subsets were FACS-sorted from PB and NT samples of a
CRC patient and TSDR analysis was conducted as detailed in the Patients and Methods section. We could not perform TSDR analysis from any T specimen due to a very
low yield of recovered cells. Color-coding represents the methylation status; numbers on the top indicate the sequential position of each CpG residue; percentages on
the right refer to the frequency of demethylated sites.
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not only of CD8C cells and Tconvs (in line with the well-
known costimulatory activity of this molecule on effector T
cells), 21 but also of Tregs (Fig. 3F), in line with data
obtained in HCC,1 suggesting that OX40 triggering may
concomitantly promote both effector and regulatory activi-
ties in the tumor microenvironment.
OX40 signal has been shown to impart a survival advantage
to T cells, and especially Tregs, under different T cell-depleting
regimens.20,22 Consistent with this idea, we could observe that
CRC patients previously treated with neoadjuvant chemother-
apy showed higher frequencies of total Tregs and especially of
OX40C Tregs, but not of OX40C Tconvs, compared to matched
controls for tumor stage and location (Fig. S3). Overall these
data support the notion that OX40 upregulation may sustain
T-Treg expansion in CRC, especially of the Helioshigh Treg
subpopulation.
Both genetic and environmental factors contribute to
determining CD39 expression
CD39, an ectonucleotidase that degrades extracellular ATP, is
constitutively expressed by Tregs and plays a well-recognized
role in mediating Treg suppressive function. CD39 expression
level in humans may be determined by both genetic and micro-
environmental factors,23 and the tumor milieu favors the
expansion of CD39high Tregs.1,24 We stratified the CRC patients
according to their genotype at the ENTPD1 single nucleotide
polymorphism (SNP, rs10748643) that is linked to CD39
expression level,23,25 and indeed we found that, in PB, this
genetic factor correlated with CD39 expression in Tconvs and
even more in Tregs (Fig. 4A). The analysis of CD39high cells
also in NT and T samples showed that (i) in all genotypes and
all districts, Tregs contained more CD39high cells than Tconvs;
(ii) in both Tconvs and Tregs, CD39high proportions increased
in NT and even more in T compared to respective PB, only in
AA and AG genotypes and not in the GG group; (iii) in both
Tconvs and Tregs, CD39high proportions increased in AG and
even more in GG compared to AA genotype, only in PB and
NT and not in the T site (Fig. 4B). Most of CD39high cells were
contained in the Helioshigh subset and included the majority of
OX40C cells; importantly, Helioshigh CD39high OX40C triple-
positive cells, which were always more frequent in Tregs than
Tconvs, gradually increased according to genotype and to dis-
trict, reaching a maximum in T samples of GG patients
(Fig. 4C). Overall, these data demonstrate that both genetic and
microenvironmental factors contribute to set CD39 expression,
Figure 3. T-Tregs express OX40, conveying proliferative signal, at highest levels. (A–C) Representative CD45RA/OX40 staining (A) and OX40C percentages in gated Tregs
and Tconvs (nD 29) (B) or Helioshigh vs. Helioslow Tregs (n D 20) (C) from PB, NT and T of CRC patients. p < 0 .05, p < 0 .01, p < 0 .005, p < 0 .001, by Wilcoxon
matched-pairs test, two-tailed. (D–E) Spearman correlations between the percentages of OX40C Tconvs and Tregs (D) and of OX40C Helioshigh or Helioslow Tregs (E).
p < 0 .05, p < 0 .01, p < 0 .001. (F) Mononuclear cells, obtained from the T sample of a representative CRC patient, were stimulated in the presence of scaled con-
centrations of rOX40L, and proliferation was estimated in gated CD8C, Tconvs (CD4CFOXP3¡) and Tregs (CD4CFOXP3C), in terms of the relative change in CFSE MFI. The
experiment was independently repeated in two patients giving similar results. p < 0 .05, p < 0 .01, by Student t test, unpaired, compared to ctrl.
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being the GG genotype or the T district sufficient to determine
the highest level of CD39high Treg frequency.
IL-17-producing Tconvs and Tregs accumulate at tumor
site and mainly within the Helioslow subsets
In line with the idea that the colonic environment promotes the
polarization of Th17 cells and Th17-like Tregs,26 we found that
both Tregs and Tconvs released IL-17 ex vivo both in NT and
even more in T samples, compared to PB; of note, the frequency
of IL-17-producing cells was always higher in Tregs than in
Tconvs, supporting the notion of a Treg preferential propensity
to Th17 polarization 14,27 (Fig. 5A). The frequency of IL-17-pro-
ducing Tregs and Tconvs showed a positive reciprocal correla-
tion in PB and T, suggesting that the two subsets may be under
the control of similar stimuli (Fig. 5B). Recent data demonstrate
that Tregs contribute to the pro-tumor Th17 polarization via an
extrinsic mechanism, i.e., IL-2 sequestration: 6 accordingly, we
could observe a significant positive association between Treg
and Th17 percentages selectively in T specimens (Fig. 5C).
We tested whether Th17-polarizing cytokines were differen-
tially released in NT or T samples. To this aim, we dosed cyto-
kine amounts in NT- and T-conditioned medium (CM), and
found that IL-1b, but not IL-6 or IL-23p19, was significantly
increased in CM from T compared to NT samples (Fig. 5D).
When the number of NT- or T-infiltrating cells was enough to
perform further analyses (in a limited number of patients), we
showed a trend toward the co-expression of IL-17 and CD39 in
T-Tregs (Fig. 5E), confirming previous observations in the liter-
ature about the role for CD39 signal in promoting Th17 polari-
zation.28 Conversely, IL-17 and Helios expression tended to be
mutually exclusive (Fig. 5F, left), according to the intrinsic sta-
bility of Helioshigh Tregs 1,16,29 and to the segregation between
Helios and RORgt expression in gut Tregs.30 OX40 expression
was similarly distributed in IL-17-positive and -negative cells
(Fig. 5F, right).
Follicular Tconvs and Tregs accumulate at both NT
and T sites
Finally, we analyzed the proportion of Tfh (BCL6CCXCR5
CFOXP3¡) and Tfr (BCL6C CXCR5CFOXP3C) cells in all dis-
tricts. Both cell types accumulated in NT and T compared to
PB; only in NT, Tfr frequency outnumbered Tfh percentage
(Fig. 6A–B). Both Tfr and Tfh cells roughly contained similar
levels of Helios and IL-17 but lower levels of CD39 and higher
levels of OX40 than total Tregs or Tconvs respectively
(Fig. 6C). The latter observation is in line with data confirming
a role for OX40/OX40L axis in T follicular cell polarization.31
Overall, these results suggest that, at NT and more at T site,
Figure 4. Both genetic and microenvironmental factors contribute to set high CD39 levels in T-Tregs. (A) Representative histogram overlay of CD39 profile in total lym-
phocytes (gray areas), gated Tconvs (black lines) or gated Tregs (dotted lines) in the PB of CRC patients, on the basis of their genotype at the SNP rs10748643 (AA, AG or
GG). (B) Percentages of CD39high cells in gated Tregs and Tconvs from PB, NT and T samples of CRC patients, stratified into AA (nD 9), AG (nD 9) or GG (nD 3) genotypes.
p< 0 .05, p< 0 .01, p< 0 .005, p< 0 .001, by Student t test, paired, between Tregs and Tconvs, by Wilcoxon matched-pairs test between different districts, and
by Student t test, unpaired, between different genotypes. (C) Concatenated analysis of Helios, CD39 and OX40 expression in different subpopulations (Tregs and Tconvs),
compartments (PB, NT and T) and genotypes (AA, AG and GG). Each pie represents grouped data from seven (AA), eight (AG) or two (GG) patients.
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multiple subpopulations of Tregs accumulate, which may dis-
play shared as well as unique features, and may concur to pro-
mote immune suppression and tumor progression through
different mechanisms.
Discussion
Among many cancer types, CRC is considered tightly linked to
inflammatory and immune events, from several points of view.
Indeed, a well-established link between CRC and chronic
inflammation, sustained by tumor cell-extrinsic as well
as -intrinsic pathways, has been recognized in multiple settings.
In particular, the IL-23/IL-17 axis has been linked to worse out-
come in CRC patients 32 and has been recognized to drive colo-
rectal carcinogenesis in experimental models,33 through a
variety of mechanisms that include a direct promotion of enter-
ocyte proliferation by IL-17.34 Conversely, CD8C T cell infiltra-
tion has been recognized as a major prognostic factor in CRC
prognosis,10 an event probably favored by follicular helper
response and tertiary lymphoid structure formation,11,35 indi-
cating the attempts of protective immune-surveillance to coun-
teract tumor progression.
In this scenario, Tregs have been proposed to potentially
exert dual functions, depending on whether their suppressive
activity mainly impacts on IL-17-dominated responses rather
than on CD8C T cell-mediated immune-surveillance.5 The
observed association between FOXP3C cell density at tumor
site and favorable prognosis4 has led to the conclusion that, in
CRC, the dominant Treg activity was the suppression of pro-
tumor inflammation, mostly driven by IL-17 axis.3,5 However,
other data indicate that the actual roles of Tregs in CRC may
be addressed to the promotion of tumor progression through
several mechanisms.6-9,13,36
Collectively, our results delineate a network of diverse Treg
subsets populating the CRC microenvironment. First, in line
with other studies (estimating Treg proportions through flow
cytometry or immunohistochemistry),7,9 we provide evidence
that the frequency of Tregs is increased at tumor site in CRC
patients similarly to what observed in other tumor types, a data
suggesting that CRC may take advantage from creating a favor-
able milieu for the accumulation of Tregs. Importantly, circu-
lating Tregs have been demonstrated to perform efficient
suppression of antitumor immunity in CRC patients.7-9
Accordingly, our results show that, in the context of CRC, Treg
depletion ex vivo unleashes effector T cell proliferation in T
specimens to a relatively higher extent compared with NT and
PB, supporting the idea that a high proportion of suppressive
Tregs are recruited into the tumor district. In addition, we
report that, in CRC, T-Tregs are enriched in Helioshigh,
CD39high and OX40C cells, phenotype compatible with a strong
suppressive activity, a high proliferative potential and a stable
regulatory program. The proportion of the triple positive subset
Figure 5. Th17-like Tregs, contained in the CD39highHelioslow subset, accumulate at T site. (A) Percentages of IL-17-producing Tregs and Tconvs in different compartments
from CRC patients (nD 14). p< 0 .05, p< 0 .01, p< 0 .005, by Student t test, paired, between Tregs and Tconvs, or by Wilcoxon matched-pairs test between differ-
ent districts. (B–C) Spearman correlations between the percentages of IL-17C Tconvs and Tregs (B) and of IL-17C Tconvs respect to total Tregs (C). p < 0 .05; ns, not sig-
nificant. (D) Cytokine amounts (estimated as the pg released in 18 h per gram of tissue) in NT- compared to T-CM from CRC patients (n D 19). p < 0 .01, by Wilcoxon
matched-pairs test. (E) Representative IL-17 versus CD39 expression in Tregs or Tconvs from the indicated districts. (F) Representative IL-17 vs. Helios (left) or OX40 (right)
expression in T-Treg and T-Tconv subsets distinguished on the basis of CD39 and IL-17 expression. Data shown are representative from one out of four patients tested.
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depended not only on the location (being maximal in the
tumor) but also on genetic factors: indeed, we found that, in
line with data in the literature,23,25 the baseline CD39 expres-
sion level was determined by a genetic polymorphism in the
ENTPD1 gene. Notably, a key role of CD39, expressed by Tregs,
in suppressing the protective antitumor immunity, has been
demonstrated in a mouse model of metastatic CRC.37 The
highly committed regulatory identity of T-Tregs is evident also
from the epigenetic characterization of the TSDR region and
from the functional evaluation of T-Tregs suppression (by
depletion experiments) directly ex vivo. We could not assess
the suppressive capacity of total T-Tregs, of single T-Treg sub-
sets, or of the CD39C Tconv population emerging in the colon,
by performing standard co-culture suppression assays, due to
insufficient cell numbers recovered from NT and T specimens.
However, it is conceivable that diverse mechanisms cooperate
in ensuring proper Treg suppression in a certain context,38
while CD39 expression may not be sufficient to impart regula-
tory activity into FOXP3¡ cells, according to data in the
literature.39
Taken together, these data speak in favor of a tumor-specific
expansion of strongly suppressive HelioshighCD39highOX40C
Tregs exhibiting a highly demethylated TSDR, committed to
the control of antitumor immunity, thus potentially playing
pro-tumor roles also in this context. Helios, associated to a
demethylated TSDR and originally recognized as thymus-
derived (t)Treg-specific,40 was subsequently detected also in
peripherally derived (p)Tregs in certain conditions,41 and more
recent studies have underscored a tight link between Helios
expression/TSDR demethylation and Treg function/epigenetic
stability, independently from Treg origin.15,16,42-45 Overall,
while the Helioslow TSDR-methylated cells virtually contains
only pTregs, especially in the colonic microenvironment
exposed to commensal microbiota,17 Helioshigh TSDR-deme-
thylated Tregs may indeed encompass a mixture of tTregs and
of “stabilized” pTregs.44
The finding that both NT- and T-Treg frequencies tended to
parallel the CD3C density (that was in turn directly correlated
with an improved survival) 10 suggests that the expansion of
suppressive Tregs may be a wide-ranging and early event in
colorectal carcinogenesis, and that Tregs seem to limit rather
than completely suppressing antitumor immunity, as the result
of the physiological Treg commitment to establish the immune
homeostasis. Consistent with this hypothesis, CD8C T cell-
dependent antitumor immunity might be more efficient in
fighting tumor without the parallel limitation by suppressive
Tregs.46 However, the estimation of total CD3C density should
be interpreted taking into consideration that also Tregs are
included in that population, and that such analysis cannot dis-
criminate between selective Treg expansion and co-recruitment
of Tregs and Tconvs/CD8C T cells.
This conclusion may appear discordant with data arising
from the analysis of Treg infiltration in CRC samples, indicat-
ing a favorable impact of FOXP3C cell infiltration on progno-
sis.4 However, it may be argued that the absolute Treg counts
simply follow and reflect the extent of the overall infiltration of
effector T cells that actually exert beneficial effects. Though rep-
resenting a good biomarker for cancer prognosis, the
Figure 6. Tfh and Tfr, enriched in the CD39lowOX40C subset, expand in both NT and T compartments. (A–B) Representative CXCR5/BCL6 staining (A) and percentage of
BCL6CCXCR5C follicular cells (B) in gated Tregs and Tconvs from PB, NT and T of CRC patients (nD 16). p < 0 .05, p< 0 .005, by Student t test, paired, between Tregs
and Tconvs, or by Wilcoxon matched-pairs test between different districts. (C) Overlay of the indicated markers in the total Treg or Tconv pool (gray areas) compared to
the T follicular subpopulation (black lines), in a representative T sample from three patients analyzed.
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estimation of Treg density may not be as relevant as supposed
in understanding their biological and immunological activities
in vivo. Rather, Treg numbers may simply reflect the potency
of antitumor immunity, as shown in breast cancer,47 and the
relative ratio between Tregs and effector T cells may be more
informative than the sole Treg count in elucidating Treg func-
tions.46 Indeed, a low intraepithelial effector/Treg ratio was
associated to a worse prognosis in CRC,36 an observation that
supported a pro-tumor effect by Tregs also in this context. In
addition, many pieces of evidence demonstrate that Tregs and
Th17 cells do not exert antagonistic activities and rather coop-
erate in a variety of contexts.48 In a mouse model of CRC, Tregs
have been shown to favor Th17 cell development and tumor
progression through the deprivation of IL-2, a cytokine able to
inhibit Th17 polarization,6 data consistent with our observation
in human CRC of a direct correlation between the frequency of
Th17 cells and the total Treg percentage in the tumor site.
Alternatively, Tregs themselves can switch to an IL-17-pro-
ducing, Th17-like, phenotype in proper conditions,49 and
human Tregs even represent preferential Th17 precursors com-
pared to other CD4C T cells.27 In this context, our data empha-
size the heterogeneity of Treg populations with different
phenotype and function that can infiltrate the tumor site.
Indeed, we also show the accumulation, at the tumor site, of
Th17-like Tregs (enriched in the HelioslowCD39highOX40C/¡
subpopulation, i.e., pTregs) that are directly correlated with the
percentage of conventional Th17 cells. On the basis of the evi-
dence showing a preferential Th-17 cell development in IL-2
deprivation conditions,6 it would be of interest to determine if
PD-1 expression, previously demonstrated to limit IL-2/STAT-
5 signaling in Tregs,50 may favor Th17-like Treg deviation. Fur-
thermore, a distinct subset of RORgtC gut-resident Tregs, con-
trolling colonic inflammation, has been recently identified,
supporting the idea that FOXP3 and RORgt may work not in
antagonism but in cooperation at the transcriptional level.30 A
RORgtC Treg subpopulation (not always coinciding with IL-
17-producing Tregs) has been found expanded in human CRC
and murine polyposis, with RORgt contributing to tumor pro-
gression through shifting tumor Treg functions from anti-
inflammatory to immune-suppressive.13 Furthermore, Tregs
can directly support tumor angiogenesis via VEGF in mouse
cancer models,51 or can directly promote tissue repair through
amphiregulin in a model of lung injury.52
Overall, these data indicate that Tregs may contribute to
tumor progression not only by exerting immune suppression
(by stable suppressive HelioshighCD39highOX40C Tregs exhibit-
ing a highly demethylated TSDR), but also by performing other
activities directly regulating tissue functions (by rather unstable
HelioslowCD39highOX40C/¡ pTregs presenting a poorly deme-
thylated TSDR region and thus prone to acquire a plastic,
Th17-like, phenotype). It would be interesting to examine
whether also NT-Tregs show some aberrant features, compared
to Tregs from the normal mucosa of healthy individuals or
patients with non-tumoral colonic diseases, and play some role
in disease evolution. In line with this idea, a high density of
FOXP3C cells in non-tumoral tissue has been associated with a
worse prognosis.4 A dysfunction also in NT-Tregs in CRC
patients may have multiple explanations: on the one side, CRC
development may condition the immunological scenario also at
distant locations in the same organ; on the other side, pre-exist-
ing immune dysfunctions in the intestine may contribute to
CRC onset/progression.
Another possible mechanism by which Tregs control the
tumor-host interaction is the modulation of lymphoid follicle
organization at the tumor site. Our data in human CRC sam-
ples show that Tfr, mostly contained in the CD39lowOX40C
subset, accumulated at NT as well at T sites, thus possibly con-
trolling Tfh response in both contexts. A dynamic analysis of
tumor infiltrating “immunome” has revealed a protective role
of Tfh response in arranging antitumor response in CRC.35 In
line with this observation, the presence of tertiary lymphoid
structures in early stage CRC has revealed a favorable prognos-
tic impact on tumor course,11 even though the association
between lymphoid aggregates (which are mostly extra-tumoral)
and prognosis remains controversial.53 The subset of Tfr cells is
specialized in suppressing Tfh responses and inhibiting the
organization of efficient lymphoid follicles.12 Therefore, it is
conceivable that Tfr play detrimental roles in tumor progres-
sion. Unfortunately, no data are yet available about a prognos-
tic relevance of Tfr in CRC progression. Moreover, Tfr may not
only influence follicle organization but also regulate local T cell
trafficking and functions. Indeed, in a mouse model of lung
cancer, Tregs have been shown to preferentially localize in ter-
tiary lymphoid structures, where they regulate antigen-present-
ing cell functions and prevent T cell activation.54
Our data indicate that both Helioshigh and Helioslow Tregs accu-
mulate at the CRC site but display distinct phenotypes and may
possibly establish a division of labor: while the former may be spe-
cialized in suppressing antitumor T cells, in favoring Tconv polari-
zation into Th17, and in differentiating into Tfr cells (mostly
OX40CCD39¡), the latter (especially OX40C/¡CD39C cells) may
be equipped for IL-17 release. In summary, the tumor microenvi-
ronment may promote the local accumulation of tTregs as well as
pTregs whose functions may converge toward pro-tumorigenic
events. Future studies will ascertain whether any of these subpopu-
lations, including the Tfr, can be considered a reliable prognostic
marker for cancer progression (in terms of density or better of rel-
ative frequency) or even a possible target for cancer
immunotherapy.
Because of the wide expression of OX40 on the different
human Treg populations analyzed within CRC, our data point
to novel roles for OX40 in promoting human Treg expansion
and/or survival. Indeed, the observation that OX40 triggering
ex vivo on tumor-infiltrating cells boosts the proliferation of
both effector (Tconv and CD8C T cell) and regulatory (Treg)
arms indicates that the immunotherapeutic efficacy of possible
OX40-agonistic compounds 55 may be limited by a concomi-
tant Treg expansion. Also, our data underscore a possible role
for OX40 in determining the preferential survival of activated
Tregs following neoadjuvant chemotherapy. Accordingly,
others have found that the frequency of Tregs expressing
markers of activation and suppression increases following bio-
logic therapy or chemoradiotherapy in head and neck
cancer 56,57 and in breast cancer 58 patients, and that Tregs are
relatively resistant to cisplatin in vitro due a higher induction
of Bcl-2 and Bcl-xL compared to Tconvs.57 Notably, OX40 sus-
tains CD4C T cell survival through the induction of these two
anti-apoptotic molecules.59 Further studies are needed to
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ascertain whether such residual immune regulatory activity
plays detrimental (suppressing antitumor immunity) or benefi-
cial (controlling systemic inflammation) roles for the host, fol-
lowing oncological therapies.
In conclusion, our work underscores the complexity of
human CRC-infiltrating Treg subpopulations and proposes
that multiple immunosuppressive and pro-carcinogenic path-
ways may be recognized as novel players in tumor-host interac-
tion and in the development of new prognostic and therapeutic
strategies.
Patients and methods
Patients and samples
PB, T and NT (collected from the upstream distal resection
margin) specimens were obtained from CRC patients not previ-
ously treated with steroid therapies and with no history of
inflammatory bowel disease or immunodeficiency. In selected
analyses, two patients that had received neoadjuvant chemo-
therapy (based on capecitabine and/or oxaliplatin, stopped at
least 1 mo before surgery) were studied. Patient characteristics
are listed in Table 1.
Peripheral blood mononuclear cells (PBMCs) were isolated
from the PB of CRC patients by density gradient centrifugation
with Lympholyte (Cedarlane) and collected in complete RPMI
1640 medium containing 10% FBS (HyClone GE Healthcare Life
Sciences), 2 mM L-glutamine (Sigma-Aldrich), penicillin/strepto-
mycin, nonessential amino acids, and sodium pyruvate (all from
EuroClone), and 50mM2-mercaptoethanol (Sigma-Aldrich).
Mononuclear cells were extracted from normal mucosa or
tumor through a modified published protocol.60 Briefly, the
fragments were minced and incubated at 37C for 20 min in
calcium- and magnesium-free Hanks’ buffered saline solution
(HBSS) containing 2.5% FBS and 1mM dithiothreitol (Sigma),
to remove mucus. The samples were then incubated in
0.75 mM EDTA (Sigma) at 37C in three rounds of 15 min
each, to remove epithelial cells. Afterwards, samples were trans-
ferred in GentleMACS C tubes (Miltenyi Biotec) containing
calcium- and magnesium-supplemented HBSS with 0.5 mg/mL
Collagenase IV (Sigma), 50 ng/mL DNAse I (Worthington),
2% FBS and 10% BSA. Tissue dissociation was made on a
GentleMACS Octo Dissociator with Heaters (Miltenyi Biotec),
by performing the program “h_tumor 01_03” thrice (with a
10-min incubation at 37C between the second and the third
round). Single cell suspensions were obtained by disrupting the
fragments with a syringe plunger over a cell strainer, washing
with cold HBSS. Then, cells were pelleted through a 40% iso-
tonic Percoll solution, and finally centrifuged over a Lympho-
lyte density gradient.
Human studies were performed in accordance with the ethi-
cal guidelines of the 1975 Declaration of Helsinki and approved
by the Institutional Ethical Committee (No. 3596). Informed
consent was obtained from all patients.
Flow cytometry
A complete list of Abs used is available as Table S1. Surface
staining was performed by incubating the cells with selected
Abs at 4C for 20 min in PBS 2% FBS. Intracellular staining of
cytokines and transcription factors was performed in accor-
dance with the manufacturer’s instructions for FOXP3 detec-
tion (eBioscience). Before IL-17 intracellular staining, cells
were stimulated for 4 h at 37C with Cell Stimulation Cocktail
plus protein transport inhibitors (eBioscience), in order to
identify the cells polarized in vivo into Th17/Th17-like. Dead
cells were excluded using Fixable Viability Dye eFluor®780
(eBioscience). Samples were acquired on the BD LSRFortessa
cell analyzer (BD Biosciences) and analyzed with FlowJo soft-
ware, version 10.0.8r1 (Treestar), and Spice software, version 5
(downloaded from http://exon.niaid.nih.gov).
Functional assays in vitro
Tregs were depleted from mononuclear cell preparations of PB,
NT and T samples by magnetic separation using CD25
microbeads (Miltenyi Biotec). Treg depletion was checked by
flow cytometry and was almost complete in all samples. Then,
cells were labeled for 15 min with CFSE (Life Technologies)
and stimulated in complete medium for 6 d in the presence of
Treg Suppression Inspector microbeads at 1:16 bead/cell ratio
(Miltenyi Biotec). CFSE dilution was analyzed by flow cytome-
try in gated CD8C T cells or Tconvs (identified as
CD4CFOXP3¡ cells). In some experiments, scaled concentra-
tions of crosslinked recombinant OX40L (RnDSystems) were
added as previously described.1
Cytokine dosage
Tissue-CM was obtained by incubating for 18 h at 37C small
tissue fragments in 1 mL of complete medium per mg of tissue.
Cytokine dosage was performed at LaboSpace (Milan, Italy)
using AimPlex multiplex kit (YLS Bio).
CD39 SNP genotyping
DNA was extracted from PBMCs according to the manufacturer’s
protocol (DNeasy blood and tissue kit, Qiagen). Analysis of the
SNP (rs10748643) in the ENTPD1 gene (Chr10:97516764) was
performed using a specific TaqMan SNP Genotyping assay
Table 1. Characteristics of all CRC patients included in the study (n D 34 , not
treated with any neoadjuvant therapy).
Age (years, mean § SD) 68 § 11
Sex
Male 20 (58.8%)
Female 14 (41.2%)
Stage (AJCC)
I 6 (17.6%)
II 9 (26.5%)
III 12 (35.3%)
IV 7 (20.6%)
Tumor location
Cecum 1 (2.9%)
Ascending colon 9 (26.5%)
Transverse colon 2 (5.9%)
Descending colon 1 (2.9%)
Sigmoid colon 13 (38.2%)
Rectum 8 (23.5%)
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(Applied Biosystems). Real-time PCRwas performed on a StepOne
system (Applied Biosystem).
Cell sorting and TSDR analysis
CD4C T cells were enriched from PB and NT mononuclear
cells using the CD4C T Cell Isolation Kit (Miltenyi Biotec), and
stained with the following antibodies: CD4C AlexaFluor488,
CD127 PECy7, CD19 APCeFluor780, CD56 APCeFluor780,
CD16 APCeFluor780, CD14 APCeFluor780 (all from eBio-
science); intracellular staining of Foxp3 and Helios was per-
formed in accordance with the manufacturer’s instructions
(eBioscience) using FOXP3 PerCPCy5.5 and Helios APC.
Helioshigh and Helioslow Tregs and Tconvs were sorted using a
FACSAria II (Becton Dickinson).
The extent of methylation in the TSDR was analyzed, accord-
ing to a published protocol,61 by performing two touchdown
nested PCRs and then sequencing the amplified TSDR region.
The CpG islands that were analyzed mapped into to the follow-
ing chromosomal positions: NCBI36:X:49004163-49004190:1
and NCBI36:X:49004227-49004251.
Immunoscoring
Immunohistochemistry was performed on formalin fixed paraffin-
embedded tissue samples using an anti-CD3 mAb and the strepta-
vidin-biotin-peroxidase complex method (Vector Laboratories).
CD3C cell density was assessed in line with procedures described
in the literature.10
Statistical analysis
Statistical analysis was performed using Prism software (version 6,
GraphPad). Unpaired Student t test, two-tailed, was used to analyze
in vitro data, while Mann–Whitney test, two-tailed, or Wilcoxon
matched-pairs test, two-tailed, was applied to compare groups of
ex vivo samples. Correlations were calculated using the nonpara-
metric Spearman’s correlation test, two-tailed. Every in vitro assay
was performed in triplicates or quadruplicates when possible. In all
graphs, bars show means §SEM. In all tests, p< 0.05 was consid-
ered statistically significant.
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